Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.43
-4.3%		$0.43
$0.15
▼
$0.97
$1.42M-0.236,843 shs249 shs
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$1.72
-9.5%		$2.87
$1.55
▼
$77.10
$394K2.218.52 million shs167,493 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.01
$0.01
$0.00
▼
$0.33
$1.45M0.746,357 shsN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$0.88
-18.2%		$1.66
$0.88
▼
$32.90
$1.57M1.84959,954 shs451,402 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-4.28%+7.45%-20.41%+34.82%-42.54%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-9.47%-20.74%-12.24%-63.01%-97.13%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%-7.50%+455.00%-81.50%+1,750.00%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-18.17%-38.20%-47.08%-75.72%-96.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.43
-4.3%		$0.43
$0.15
▼
$0.97
$1.42M-0.236,843 shs249 shs
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$1.72
-9.5%		$2.87
$1.55
▼
$77.10
$394K2.218.52 million shs167,493 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.01
$0.01
$0.00
▼
$0.33
$1.45M0.746,357 shsN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$0.88
-18.2%		$1.66
$0.88
▼
$32.90
$1.57M1.84959,954 shs451,402 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-4.28%+7.45%-20.41%+34.82%-42.54%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-9.47%-20.74%-12.24%-63.01%-97.13%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%-7.50%+455.00%-81.50%+1,750.00%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-18.17%-38.20%-47.08%-75.72%-96.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00
N/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
1.00
SellN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest IMCC, ATXI, NKGN, and NXTS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/15/2026
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$45.80M0.01N/AN/A($14.81) per share-0.12
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/A($2.68) per shareN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$210K6.10N/AN/A$39.70 per share0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$0.850.02N/AN/AN/A-471.57%-296.50%11/13/2026 (Estimated)
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$8.10M-$60.66N/AN/AN/A-39.62%N/A-58.32%11/16/2026 (Estimated)
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$1.68N/AN/AN/AN/AN/A-479.36%N/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-$4M-$96.07N/AN/AN/AN/A-304.79%-178.91%N/A

Latest IMCC, ATXI, NKGN, and NXTS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A-$0.34N/A-$9.92N/A$5.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
2.70
2.70
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
0.56
0.46
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
0.12
3.72
3.72

Institutional Ownership

CompanyInstitutional Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
7.68%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
61.24%

Insider Ownership

CompanyInsider Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
8.60%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
5.91%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
6.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
43.30 million2.02 millionNot Optionable
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
44207,000195,000Not Optionable
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A130.60 million40.29 millionNot Optionable
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
91.45 million1.36 millionN/A

Recent News About These Companies

Nexentis deploys MitoCareX computational drug discovery infrastructure on Google Cloud
October 7 at 12:28 PM  |  msn.comhttps://www.msn.com/en-us/news/other/nexentis-deploys-mitocarex-computational-drug-discovery-infrastructure-on-google-cloud/ar-AA2dLnOU
Nexentis Subsidiary MitoCareX Deploys Computational Drug Discovery Infrastructure on Google Cloud Platform
October 7 at 7:51 AM  |  quiverquant.comQ
Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
October 7 at 7:32 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376398/0/en/nexentis-mitocarex-bio-deploys-its-computational-drug-discovery-infrastructure-on-google-cloud.html
NXTS - Nexentis Technologies Inc.
September 26, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/NXTS/historical-price-quotes
Nexentis nomina esperto di chimica computazionale nel consiglio scientifico
September 25, 2026  |  it.investing.comhttps://it.investing.com/news/company-news/nexentis-nomina-esperto-di-chimica-computazionale-nel-consiglio-scientifico-93CH-3561302
Nexentis beruft Experten für computergestützte Chemie in wissenschaftlichen Beirat
September 25, 2026  |  de.investing.comhttps://de.investing.com/news/company-news/nexentis-beruft-experten-fur-computergestutzte-chemie-in-wissenschaftlichen-beirat-93CH-3676265
Nexentis Technologies Announces Appointment of Prof. Dan T. Major to MitoCareX Scientific Advisory Board
September 24, 2026  |  quiverquant.comQ
Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
September 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368223/0/en/nexentis-mitocarex-strengthens-its-computational-drug-discovery-capabilities-with-appointment-of-prof-dan-t-major-to-scientific-advisory-board.html
Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
September 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367366/0/en/nexentis-mitocarex-evaluates-expanded-protein-capabilities-to-enhance-flexibility-and-support-future-drug-discovery.html
Nexentis Technologies Faces Nasdaq Compliance and Delisting Risk
September 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nexentis-technologies-faces-nasdaq-compliance-and-delisting-risk?utm_source=marketbeat.com&utm_medium=referral
Nexentis Technologies Inc.: Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
July 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69143766-nexentis-technologies-inc-nexentis-technologies-subsidiary-mitocarex-bio-selects-transport-protein-candidate-for-drug-discovery-campaign-399.htm
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334228/0/en/nexentis-technologies-subsidiary-mitocarex-bio-selects-transport-protein-candidate-for-drug-discovery-campaign.html
Nexentis Technologies Earnings Estimates, EPS & Revenue | NASDAQ:NXTS
July 18, 2026  |  benzinga.comhttps://www.benzinga.com/quote/NXTS/earnings
Nexentis Technologies Insider Trading Activity | NASDAQ:NXTS | Benzinga
July 17, 2026  |  benzinga.comhttps://www.benzinga.com/quote/NXTS/insider-trades
Nexentis Technologies Inc NXTS
July 7, 2026  |  morningstar.comM
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323166/0/en/nexentis-subsidiary-mitocarex-bio-advances-slc-transporter-drug-discovery-with-broad-analysis-and-international-ai-initiative.html
Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS)
June 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/nexentis-shares-rise-after-solar-project-monetisation-agreement-nxts/ar-AA26OnVs
Nexentis Technologies Announces Addendum on Melz Solar Project Loan and Profit Rights, Reflecting $14.5 Million Project Valuation
June 29, 2026  |  quiverquant.comQ
Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
June 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/29/3318926/0/en/nexentis-announces-monetization-of-part-of-its-melz-solar-investment-at-14-5-million-project-valuation-significant-premium-to-initial-investment.html
Nexentis Technologies Announces Registered Direct Offering and Warrants
June 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nexentis-technologies-announces-registered-direct-offering-and-warrants?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avenue Therapeutics stock logo

Avenue Therapeutics NASDAQ:ATXI

$0.43 -0.02 (-4.28%)
As of 10/8/2026 03:53 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

IM Cannabis stock logo

IM Cannabis NASDAQ:IMCC

$1.72 -0.18 (-9.47%)
Closing price 10/8/2026 04:00 PM Eastern
Extended Trading
$1.77 +0.05 (+2.91%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.01 0.00 (0.00%)
As of 10/7/2026

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Nexentis Technologies stock logo

Nexentis Technologies NASDAQ:NXTS

$0.88 -0.20 (-18.17%)
Closing price 10/8/2026 04:00 PM Eastern
Extended Trading
$0.87 -0.01 (-1.22%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company's products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas